Business Wire2h
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Ever-Growing USA on MSN9h
Cell Line Development Process – Challenges and Best Practices
Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.
precisionmedicineonline15h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...